Clinical Trial Update: Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and safety study of a single IV dose of MK-3866 in participants with renal impairment and healthy controls has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• MK-3866

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Impairment | Phase 1 | Status: COMPLETED | Results posted: 2019-04-19